Top Biotech Companies With Best Stability & Growth (3,590)

Strong Revenue Growth: Revenue is accelerating, with FY2025 up 19% and Q1 2026 up 22%, and guidance of $92–$94M implies about 20–22% further growth in 2026. Record analysis volumes and rising net dollar retention support the trajectory.

Strategic Partnerships: High-profile collaborations with Memorial Sloan Kettering (MSK‑ACCESS and MSK‑IMPACT), AstraZeneca, MD Anderson, and large U.S. health systems expand access and credibility for new applications. These relationships are highlighted as drivers of continued double-digit growth through 2026.

Market Expansion: The company is adding customers and scaling usage globally—reaching 537 core genomics customers and a record 108,000 analyses in Q1 2026—with particularly strong momentum in the U.S. and APAC. Reaffirmed U.S. expansion and new application launches are expected to sustain this momentum.

Investor Backing & Capital Strength: Fresh capital arrived via a $50M April 2026 investment from Boehringer Ingelheim alongside an earlier Series C led by Dassault Systèmes/Medidata, extending resources for commercialization. The concurrent transfer of CT‑155 commercialization/marketing rights signals committed funding tied to revenue‑bearing activities.

Strategic Partnerships: Long‑running collaborations deepened with Boehringer Ingelheim (commercialization rights for CT‑155) and Otsuka (Rejoyn), while Dassault Systèmes/Medidata broadened a technology partnership to support scale‑up. A January 2026 partnership with Ultrahuman expands reach beyond traditional PDT channels.

Product Line Growth: Recent FDA authorizations for CT‑132 (episodic migraine) and Rejoyn (MDD) broaden the platform and advance the company toward launches. These milestones are highlighted as bolstering credibility for future products.

Strong Revenue Growth: ARR is estimated to have surpassed $200M by May 2024 with roughly 27% year over year growth, indicating ongoing top-line expansion. While slower than pre-2022 hypergrowth, this still reflects material scaling at enterprise revenue levels.

Market Expansion: The company reports welcoming 240 new customers in 2024 and now powers over 1,300 biotechnology companies. This evidences continued penetration and up-market traction in life-sciences R&D.

Product Line Growth: New modules and AI capabilities launched in 2024, including Benchling Bioprocess and analytics features, broadened the platform beyond research into development and data analysis. The PipeBio acquisition further strengthened high-throughput biologics and AI-assisted discovery.

Strong Revenue Growth: Revenue is rising, with 2025 total revenue reaching roughly $147M and U.S. Galleri revenue about $136–137M. Early 2026 momentum continued as Galleri revenue increased to $39.8M on sharply higher test volumes (over 56,000 in Q1).

Strategic Partnerships: Distribution and access are expanding through integrations with Quest Diagnostics and Epic’s EHR that streamline ordering and broaden provider access. Additional channels such as Priority Health’s employer offering indicate widening availability.

Investor Backing & Capital Strength: Capital resources are sizable, including $823.1M in cash and securities as of March 31, 2026 and a $110M equity investment from Samsung entities. Management indicates a multiyear runway into 2030, supporting continued trials and commercialization.

Product Line Growth: Launched and acquired products are scaling, with oncology assets from the Seagen deal and brands such as Padcev, oncology biosimilars, Nurtec, Lorbrena, Abrysvo, Eliquis, and the Vyndaqel family cited as key contributors. Early‑2026 updates describe a meaningful uptick from these newer and in‑line medicines.

Innovation-Driven Growth: Management highlights a robust late‑stage pipeline with numerous pivotal study starts planned in 2026 and catalysts across oncology, vaccines, and metabolic disease. Programs such as an ADC (sigvotatug vedotin) and a GLP‑1 RA (berobenatide) are positioned to convert into future approvals and launches.

Diversified Revenue Streams: Growth beneath the surface is coming from multiple non‑COVID franchises rather than a single product, spanning oncology (including Seagen’s ADCs), vaccines, neurology, and cardiovascular. This breadth is helping to offset normalization in COVID‑related sales.

Product Line Growth: Multiple 2026 launches and updates, including Flatiron Telescope, AI‑extracted real‑world progression, a new AI data‑quality framework, and harmonized multinational datasets, signal an expanding offering. A strong 2026 scientific presence (e.g., ASCO/ISPOR) showcases next‑generation capabilities aligned to growing use cases.

Market Expansion: International build‑out is evident in first AI‑powered prostate cancer datasets for the UK and Germany and new collaborations across the UK and Europe. Company materials also highlight a markedly larger multinational network spanning the UK, Germany, and Japan.

Strategic Partnerships: Collaborations with Unicancer for regulatory‑grade evidence and point‑of‑care integrations with Abbott and Quest indicate deepening enterprise engagement. Participation in ecosystem programs and multi‑year collaborations suggests a partner‑led growth approach.

Strong Revenue Growth: Total revenue grew 23% year over year to $255.9M in 2025, with software up 10.6% and drug discovery more than doubling to $56.4M. Guidance for 2026 points to 10–15% software ACV growth, and Q1 2026 ACV rose 12% year over year.

Strategic Partnerships: Royalty‑eligible collaborative programs increased to 16 by year‑end 2025, with multiple partner milestones (e.g., Takeda’s TYK2 from Nimbus, Structure Therapeutics updates) and integrations like Lilly’s TuneLab in LiveDesign signaling ecosystem momentum. These relationships can generate milestones and potential royalties that support future growth.

Investor Backing & Capital Strength: Cash and marketable securities were about $402M at year‑end 2025 (approximately $406M at Q1 2026), and operating expenses are guided below 2025 levels for 2026. This liquidity and cost discipline provide runway to advance the hosted transition and the discovery portfolio.

Strong Revenue Growth: Revenue is reported at about $1.27B for 2025 (~80–83% YoY), with Q4 2025 at $367.2M (+83% YoY) and Q1 2026 at $348.1M (+36% YoY); full‑year 2026 is guided to $1.59–$1.60B (~25% growth). Segment data show Diagnostics up 34.7% and Data & Applications up 40.5% YoY in Q1 2026.

Strategic Partnerships: Record total contract value exceeding $1.1B and multi‑year collaborations with AstraZeneca, Merck, Gilead, and Bristol Myers Squibb are highlighted. These arrangements support growth in data/software lines and add forward revenue visibility.

Product Line Growth: MRD testing reached ~6,500 in Q1 2026 (up ~500% YoY), and acquisitions of Ambry Genetics, Paige.AI, and Deep 6 AI broaden testing and AI capabilities. Management points to horizontal integration and cross‑selling (e.g., with Ambry) as contributors to expected growth.

Innovation-Driven Growth: AI site selection and AI patient pre-screening launched in 2025–2026 are described as streamlining screening and improving enrollment efficiency. These releases signal a deepening product footprint aligned to faster activation and more representative enrollment.

Strategic Partnerships: A 2025 data partnership with RealTime eClinical Solutions and highlighted work with major pharma logos are presented as ecosystem validation and traction. These collaborations integrate site performance data and extend marketplace reach.

Market Expansion: The network is portrayed as growing from about 5,500 to 6,000+ research sites across 50+ countries into 2026. Sponsor materials and industry posts indicate steady expansion of marketplace breadth.

Investor Backing & Capital Strength: Capital raised is described as substantial, with a $372M Series D in June 2024 led by a16z and participation from Sanofi, explicitly earmarked to grow the pipeline and AI platform. References to $600M+ in total funding and ongoing hiring point to a reinforced capital base supporting expansion.

Strategic Partnerships: Collaborations with Sanofi and OpenAI are presented as first-in-class efforts to apply AI across drug development, signaling external validation and increased resourcing. A 2025 Sanofi licensing deal worth up to €545M further indicates the capability to progress and transact assets with blue‑chip partners.

Product Line Growth: Pipeline activity is shown to be broadening via in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor in Dec 2025) and movement into the clinic, including first‑in‑human dosing on June 9, 2026. Together, these moves suggest more programs are entering and advancing through clinical stages.

Strong Revenue Growth: Revenue grew significantly year over year with continued quarterly momentum, led by rising clonoSEQ MRD volumes and management guidance for further expansion in 2026.

Cost & Operational Efficiency: Cash burn declined meaningfully and adjusted profitability metrics improved, with the MRD segment achieving positive contribution and initiatives underway to enhance margins and scale.

Investor Backing & Capital Strength: Analyst sentiment is predominantly positive with recent upgrades and targets above current levels, and the company enters 2026 with a solid cash position and a stated goal of positive free cash flow.